Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - abamectin; praziquantel - oral paste - abamectin anthelmintic active 3.7 mg/g; praziquantel anthelmintic active 46.2 mg/g - parasiticides - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - ascarid - parasacris equorium | bots - gasterophilus spp. | cutaneous onchocerciasis | intestinal threadworm - s. westeri | large mouth stomach worm | large strongyles - strongylus edentatus | large strongyles - strongylus equinus | large strongyles - strongylus vulgaris | large strongyles - triodontophorus spp. | lungworm - dictyocaulus arnfieldi | pinworm - oxyuris equi | small strongyles | small strongyles - cylicocyclus spp. | small strongyles - cylicodontophorus spp | small strongyles - cylicostephanus spp. | small strongyles - gyalocephalus spp. | small strongyles-benzimidazole resistant | stomach hair worm | summer sores | tapeworm - anoplocephala magna | tapeworm - anoplocephala perfoliata | tapeworm - paranoplocephala mammillana | bloodworm | bot fly | bot fly - oral and gastric sta | coronocyclus spp. | cutaneous larvae | cyalocephalus spp. | cyathostomum spp. | cylicocyclus spp. | cylicodontophorus spp. | cylicostephanus spp. | gasterophilus haemorrhoidalis | gasterophilus inermis | gasterophilus i

Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

international animal health products pty ltd - bromhexine hydrochloride; trimethoprim; sulfadimidine - oral paste - bromhexine hydrochloride guanidine active 9.0 mg/g; trimethoprim pyrimidine active 90.0 mg/g; sulfadimidine sulfanyl active 450.0 mg/g - antibiotic & related - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - infections of the respiratory tract | organisms sensitive to combination of | acute respiratory infections | bronchiseptica | bronchitis | pharyngitis | pneumonia | tonsillitis

Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - phenylbutazone - oral paste - phenylbutazone analgesic active 1.0 g/5ml - musculoskeletal system - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - anti-inflammatory agent | antipyretic | bone soreness | bruising | bursitis | inflammatory rheumatic arthrit | joint disease | ligament sprains | muscle soreness | osteoarthritis | platelet activity | rheumatism | sprains | strains | tendon sprains | traumatic swelling

États-Unis - anglais - NLM (National Library of Medicine)

american health packaging - chlorhexidine gluconate (unii: mor84mud8e) (chlorhexidine - unii:r4ko0dy52l) - chlorhexidine gluconate oral rinse should not be used by persons who are known to be hypersensitive to chlorhexidine gluconate or other formula ingredients.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - levetiracetam, quantity: 10 % w/v - oral liquid, solution - excipient ingredients: acesulfame potassium; propyl hydroxybenzoate; purified water; maltitol solution; glycerol; sodium citrate dihydrate; methyl hydroxybenzoate; ammonium glycyrrhizinate; citric acid monohydrate; flavour - levetiracetam-aft oral solution is indicated for:,use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation,,monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme),and,add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).,levetiracetam-aft concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.

États-Unis - anglais - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - diazepam (unii: q3jtx2q7tu) (diazepam - unii:q3jtx2q7tu) - diazepam 5 mg in 5 ml - diazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. in acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. the effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. the physician should periodically reassess the usefulness of the drug

États-Unis - anglais - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - lorazepam (unii: o26fzp769l) (lorazepam - unii:o26fzp769l) - lorazepam 2 mg in 1 ml - lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. the physician should periodically reassess the usefulness of the drug for the individual patient. lorazepam is contraindicated in patients with: lorazepam is a schedule iv controlled substance. lorazepam is a benzodiazepine and a cns depressant with a potential for abuse and addiction. abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a healthcare provider or for whom it was not prescribed. drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence. even taking benzodiazepines as prescribed may put patients at risk for abuse and misuse of their medication. abuse and misuse of benzodiazepines may lead to addiction. abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death. benzodiazepines are often sought by individuals who abuse drugs and other substances, and by individuals with addictive disorders (see warnings: abuse, misuse, and addiction ). the following adverse reactions have occurred with benzodiazepine abuse and/or misuse: abdominal pain, amnesia, anorexia, anxiety, aggression, ataxia, blurred vision, confusion, depression, disinhibition, disorientation, dizziness, euphoria, impaired concentration and memory, indigestion, irritability, muscle pain, slurred speech, tremors, and vertigo. the following severe adverse reactions have occurred with benzodiazepine abuse and/or misuse: delirium, paranoia, suicidal ideation and behavior, seizures, coma, breathing difficulty, and death. death is more often associated with polysubstance use (especially benzodiazepines with other cns depressants such as opioids and alcohol). physical dependence lorazepam may produce physical dependence from continued therapy. physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. abrupt discontinuation or rapid dosage reduction of benzodiazepines or administration of flumazenil, a benzodiazepine antagonist, may precipitate acute withdrawal reactions, including seizures, which can be life-threatening. patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages (i.e., higher and/or more frequent doses) and those who have had longer durations of use (see warnings: dependence and withdrawal reactions ). to reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam or reduce the dosage (see dosage and administration: discontinuation or dosage reduction of lorazepam and warnings ). tolerance tolerance to lorazepam may develop from continued therapy. tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose). tolerance to the therapeutic effect of lorazepam may develop; however, little tolerance develops to the amnestic reactions and other cognitive impairments caused by benzodiazepines.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - levetiracetam, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: acesulfame potassium; purified water; maltitol solution; methyl hydroxybenzoate; ammonium glycyrrhizinate; citric acid monohydrate; propyl hydroxybenzoate; sodium citrate dihydrate; glycerol; flavour - keppra (film coated tablets and oral solution) is indicated for - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation, - monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. - add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and - add on therapy in the treatment of primary generalised tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige). keppra concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - amoxicillin trihydrate - oral suspension - 50mg/1ml

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - amoxicillin trihydrate - oral suspension - 25mg/1ml